Pioneering RNA Modification Beyond Rare Diseases by Exploring Novel Editing Technologies & Targeting Multiple Mutations to Remove the Barriers to Treating Common Diseases

• Rethinking editing machinery to edit beyond point mutations and specifically modify multiple target sites simultaneously
• Preclinical data to demonstrate the potential of RNA editing outside of rare disease
• Strategically investigating common disease targets to attract investment and pharma partnerships

Speakers:

Gerard Platenburg

Chief Scientific Officer & co-founder

ProQR Therapeutics